- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00218595
DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1
Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems
The purpose of this study is to examine the efficacy of DBT compared to a standard drug counseling approach for the treatment of opiate addiction and borderline personality disorder (BPD). Treatment research has repeatedly shown that retention of BPD and substance addicted individuals to be the among the most challenging for therapists. DBT has established itself as one of the most effective treatments for treatment retention of these patients and for reducing parasuicidal and self-injurious behaviors.
This study is one of two in a multi-site RCT for the treatment of opiate addiction. DBT has been shown to be efficacious for the treatment of BPD patients and it has been extended in this study to target addictive behaviors in these patients. The study consists of three treatment parts: weekly individual and group therapy and suboxone maintenance medication. Participants are provided therapy on a weekly basis for one year and suboxone for 2 years. Assessments for tracking outcome are conducted every 4 months.
It is hypothesized patients in the DBT condition will show a reduction of substance use, parasuicidal and other psychological difficulties and these gains will be maintained through the year of follow-up assessments. In addition, it is predicted that adherence to DBT treatment protocols will be associated with improved outcomes. Finally, it is predicted that treatment "dosage" (average hours of therapy/week) will be positively related to clinical improvement.
Study Overview
Status
Intervention / Treatment
Detailed Description
The study design is a two arm randomized clinical trial comparing a one year treatment program of Dialectical Behavior Therapy (DBT) + suboxone for heroin addicted individuals meeting criteria for borderline personality disorder (BPD) to a one year program of standard drug counseling (I/GDC) + suboxone. Drug counseling will consist of manualized individual sessions + group therapy. Participants in both conditions will be prescribed psychotropic medications following a standardized medication protocol developed specifically for BPD individuals. Each site will enroll 86 clients with both treatment conditions being conducted at each site. Assessments measuring drug use, suicidal behaviors, retention and other treatment-related behaviors, general psychopathology and functioning, and increases in behavioral skills will be given at four month intervals for two years
There are five outcome domains of principal interest in this study:
- Drug use: The primary outcome measure here is proportions of urinalysis (UA) coded positive for opiates;
- Suicidal behaviors: The primary outcome measure here is number of suicides + suicide attempts. The domain of suicidal behaviors also includes (a) the number, medical risk, risk/rescue score and suicide intent of all parasuicide, (b) the number of suicide threats and suicide crises, and (c) the level of suicidal ideation and suicide intent;
- Therapy-interfering behaviors: The primary outcome measure here is maintenance in therapy;
- Quality of life interfering behaviors: The primary outcome measure here is combined number of days on a psychiatric inpatient unit + days in jail (THI, SHI);
- Behavioral skills: The primary outcome measure here is the DBT Skills scale score from the Revised Ways of Coping Checklist (RWCCL);
- Risky sexual behavior: the primary outcome measure here is the number of risky sexual behaviors in the time period [Casual Partners questionnaire revised [CPQ-R] and diary card].
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets SCID-I criteria for opiate dependence.
- Meets IPDE and SCID criteria for BPD (DSM-IV)
- Over 18 years old
- Resides within commuting distance of treatment
- Consents to outpatient treatment for drug addiction
Exclusion Criteria:
- Bipolar, Schizophrenia, Schizophreniform, or Schizoaffective Disorders, Psychosis NOS
- IQ less than 70; life threatening anorexia; current and chronic absence of shelter; impending jail/prison for more than three weeks (problems which by their presence or severity preclude ability to attend or understand treatment and/or requires priority treatment over SUD treatment)
- Court order to treatment, court order to treatment or to jail, or agency order to treatment or loss of child custody (due to consequent inability to freely drop-out of treatment)
- Is pregnant, plans to become pregnant during treatment phase, or becomes pregnant before random assignment to study condition
- Is unable to tolerate suboxone induction phase
- Is currently stable on an adequate dose of methadone
- Current benzodiazepine abuse or dependence
- Refuses: to discontinue current mental health or drug abuse treatment or random assignment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DBT
|
Dialectical behavior therapy plus opiate replacement medication.
|
ACTIVE_COMPARATOR: I/GDC
|
Individual and group drug counseling plus opiate replacement medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Psychological assessment interview
Time Frame: Baseline, 4-month, 8-month, 12-month, 16-month, 20-month, 24-month
|
Baseline, 4-month, 8-month, 12-month, 16-month, 20-month, 24-month
|
Urinalysis
Time Frame: 3x/week during active treatment; 1x/week during follow-up year
|
3x/week during active treatment; 1x/week during follow-up year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pre- and post-session therapist and client questionnaires
Time Frame: 1x/week during active treatment
|
1x/week during active treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00010957
- 5R01DA026454-03 (NIH)
- R01-17372-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dialectical Behavior Therapy
-
Soroka University Medical CenterUnknownEmotional Dysregulation | Dialectical Behavioral TherapyIsrael
-
Alexandria UniversityCompleted
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedDialectical Behavior Therapy + Pharmacotherapy | Standard of Care Psychotherapy + PharmacotherapyUnited States
-
Shalvata Mental Health CenterNot yet recruitingPlacebo | Treatment 1:Dialectical Behavior Therapy (DBT) | Treatment 2:Dynamic Deconstructive Psychotherapy (DDP)
-
Uppsala UniversityCompleted
-
University of Rhode IslandCompletedCognitive Behavior Therapy | Relaxation Therapy | Motivational Intervention | Nicotine AnonymousUnited States
-
Hong Kong Baptist UniversityCompletedCognitive Behavior Group TherapyHong Kong
-
Basque Health ServiceUnknownHealth Promotion | Health Behavior | Health Education | Patient Education | Counseling | Behavior TherapySpain
-
University Hospital, BordeauxCentre National de la Recherche Scientifique, FranceRecruitingObesity | Addiction | Craving | Cognitive Behavioral Therapy | Cognitive Remediation TherapyFrance
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; New York University; U.S. Department of EducationCompletedExecutive Function | Schools | Behavior Therapy | Behavioral ResearchUnited States
Clinical Trials on DBT
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedSuicide | Borderline Personality DisorderUnited States
-
University Hospital, MontpellierINSERM 1061, " Neuropsychiatry: epidemiological and clinical research", MontpellierWithdrawnFemale | Borderline Personality DisorderFrance
-
Rivierduinen, Centre for Personality disorders...Erasmus Medical CenterUnknownBorderline Personality DisorderNetherlands
-
University of Maryland, BaltimoreRecruitingSuicide | PsychosisUnited States
-
Mental Health Services in the Capital Region, DenmarkUniversity of Copenhagen; Lundbeck FoundationCompletedSuicide | Borderline Personality DisorderDenmark
-
ArkinAmsterdam UMC, location VUmc; Ziekenhuis Amstelland; Meander Medisch Centrum; Sinai... and other collaboratorsRecruitingPosttraumatic Stress Disorder (PTSD) | Borderline Personality Disorder (BPD)Netherlands
-
Bowling Green State UniversityUnknownOverweight and Obesity | Emotional Eating
-
Haukeland University HospitalRecruitingSuicidal Ideation | Self-harm | Suicide and Self-harmNorway
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedSuicide | Post-traumatic Stress Disorder | Self-injurious BehaviorUnited States
-
Kaiser PermanenteNational Institute of Mental Health (NIMH)CompletedSuicidal Ideation | Suicide, Attempted | SuicideUnited States